Physician profile
Toby C Long
NPI 1952558272
$3,248.69
in general payments reported to CMS, 2019-2025
38 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $233 · 2021: $467 · 2022: $645 · 2023: $732 · 2024: $468 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,629 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.79 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $329.27 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $299.10 | 2021-2025 | Rexulti |
| Pfizer INC. | $279.21 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $267.34 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.13 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $230.54 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $189.34 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $130.40 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Mylan Specialty L.P. | $103.60 | 2022-2023 | Yupelri, Yupelri |
| Biohaven Pharmaceuticals, INC. | $91.08 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.65 | 2022-2025 | |
| Amgen INC. | $84.35 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $80.78 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $76.86 | 2019-2024 | Vaxneuvance, Gardasil 9, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $66.65 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toby Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.